NZ549430A - Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone - Google Patents

Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone

Info

Publication number
NZ549430A
NZ549430A NZ549430A NZ54943005A NZ549430A NZ 549430 A NZ549430 A NZ 549430A NZ 549430 A NZ549430 A NZ 549430A NZ 54943005 A NZ54943005 A NZ 54943005A NZ 549430 A NZ549430 A NZ 549430A
Authority
NZ
New Zealand
Prior art keywords
ppm
hydroxycodeinone
oxycodone hydrochloride
oxycodone
composition
Prior art date
Application number
NZ549430A
Other languages
English (en)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ549430(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NZ549430A publication Critical patent/NZ549430A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ549430A 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone NZ549430A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10
PCT/US2005/010666 WO2005097801A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Publications (1)

Publication Number Publication Date
NZ549430A true NZ549430A (en) 2010-05-28

Family

ID=35124996

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ549430A NZ549430A (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
NZ601326A NZ601326A (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
NZ602862A NZ602862A (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ601326A NZ601326A (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
NZ602862A NZ602862A (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Country Status (38)

Country Link
US (35) US7129248B2 (cg-RX-API-DMAC10.html)
EP (7) EP2426132B1 (cg-RX-API-DMAC10.html)
JP (8) JP4912294B2 (cg-RX-API-DMAC10.html)
KR (12) KR101410141B1 (cg-RX-API-DMAC10.html)
CN (5) CN1960994B (cg-RX-API-DMAC10.html)
AP (1) AP2232A (cg-RX-API-DMAC10.html)
AR (1) AR049012A1 (cg-RX-API-DMAC10.html)
AT (2) ATE501150T1 (cg-RX-API-DMAC10.html)
AU (2) AU2005230826C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0508758B8 (cg-RX-API-DMAC10.html)
CA (3) CA2557845C (cg-RX-API-DMAC10.html)
CR (2) CR8593A (cg-RX-API-DMAC10.html)
CY (5) CY1111487T1 (cg-RX-API-DMAC10.html)
DE (2) DE202005021371U1 (cg-RX-API-DMAC10.html)
DK (6) DK2426132T3 (cg-RX-API-DMAC10.html)
EA (1) EA013208B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066953A (cg-RX-API-DMAC10.html)
ES (6) ES2566363T3 (cg-RX-API-DMAC10.html)
FI (1) FI7843U1 (cg-RX-API-DMAC10.html)
HR (5) HRP20110425T4 (cg-RX-API-DMAC10.html)
HU (3) HUE029913T2 (cg-RX-API-DMAC10.html)
IL (8) IL178038A (cg-RX-API-DMAC10.html)
LT (2) LT2314589T (cg-RX-API-DMAC10.html)
MA (1) MA28492B1 (cg-RX-API-DMAC10.html)
ME (4) ME01299B (cg-RX-API-DMAC10.html)
MX (2) MX363228B (cg-RX-API-DMAC10.html)
MY (3) MY143205A (cg-RX-API-DMAC10.html)
NO (1) NO337669B1 (cg-RX-API-DMAC10.html)
NZ (3) NZ549430A (cg-RX-API-DMAC10.html)
PE (1) PE20050880A1 (cg-RX-API-DMAC10.html)
PL (5) PL2305683T3 (cg-RX-API-DMAC10.html)
PT (5) PT2305683E (cg-RX-API-DMAC10.html)
RS (5) RS53891B1 (cg-RX-API-DMAC10.html)
SG (3) SG10201406658VA (cg-RX-API-DMAC10.html)
SI (5) SI2319846T1 (cg-RX-API-DMAC10.html)
TW (3) TWI365880B (cg-RX-API-DMAC10.html)
WO (1) WO2005097801A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607181B (cg-RX-API-DMAC10.html)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1861405E (pt) * 2005-03-04 2009-07-27 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos
WO2007011819A2 (en) * 2005-07-15 2007-01-25 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP2402346A1 (en) * 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (ja) 2006-03-02 2015-04-01 マリンクロッド エルエルシー 低レベルのアルファ，ベータ−不飽和ケトン化合物を伴うモルフィナン−６−オン生成物の製造方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DK2073636T3 (da) * 2006-10-17 2012-11-19 Penick Corp Fremgangsmåde til fremstilling af oxymorphon
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CN101652370A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 制备14-羟基可待因酮水平减少的羟考酮的方法
ES2378710T3 (es) * 2006-12-04 2012-04-17 Noramco, Inc. Procedimiento para reducir impurezas en la base de oxicodona
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2125824T5 (pl) * 2007-03-23 2024-11-04 SpecGx LLC Ulepszony sposób wytwarzania oksymorfonu z oripawiny
WO2008130553A1 (en) 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
BR112012001466A2 (pt) * 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) * 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
SG184523A1 (en) 2010-05-10 2012-11-29 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
CA2936749C (en) 2010-06-11 2019-07-09 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
CA2804101C (en) * 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
US9414988B2 (en) 2011-09-05 2016-08-16 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
AU2012310251B2 (en) 2011-09-16 2016-01-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20140341984A1 (en) 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2603278T3 (es) 2011-12-09 2017-02-24 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
EA028092B1 (ru) 2012-07-16 2017-10-31 Родс Текнолоджис Способ усовершенствованного синтеза опиоидов
NZ628695A (en) * 2012-07-16 2016-02-26 Rhodes Technologies Process for improved opioid synthesis
SI2880037T1 (sl) * 2012-08-03 2019-04-30 Johnson Matthey Public Limited Company Postopek za pripravo oksikodona
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
EP3027622B8 (en) 2013-08-02 2019-06-12 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
US9193737B2 (en) 2013-11-07 2015-11-24 Mallinckrodt Llc Production of 6-hydroxy morphinans without the isolation of intermediates
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
MX379406B (es) 2014-01-15 2025-03-11 Rhodes Tech Proceso para la síntesis mejorada de oximorfona.
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CA2954600A1 (en) * 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3067718A1 (en) 2017-06-20 2018-12-27 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296916C (cg-RX-API-DMAC10.html) *
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE286431C (cg-RX-API-DMAC10.html)
US420098A (en) * 1890-01-28 Mowing-machine
US1485673A (en) 1924-03-04 Ministrator
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (cg-RX-API-DMAC10.html) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (cg-RX-API-DMAC10.html) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) * 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
EP1121234B1 (en) * 1998-10-14 2003-10-01 Gyros AB A matrix and method of producing said matrix
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
NZ529661A (en) * 2001-06-05 2006-03-31 Control Delivery Systems Sustained-release analgesic compounds
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
AU2003235678A1 (en) * 2002-01-15 2003-07-30 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
PT1578350E (pt) * 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
MXPA04010769A (es) 2002-04-29 2005-07-05 Alza Corp Metodos y formas de dosificacion para suministro controlado de oxicodona.
CA2455586C (en) * 2002-05-27 2012-01-03 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
CA2487786A1 (en) 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP1537118A1 (en) * 2002-08-15 2005-06-08 Noramco, Inc. Oxycodone-hydrochloride polymorhs
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur PHARMACEUTICAL COMPOSITION
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
PT1861405E (pt) 2005-03-04 2009-07-27 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos
DE602006019246D1 (de) 2005-06-16 2011-02-10 Mallinckrodt Inc Synthetische route zu 14-hydroxylopiaten über 1-halogenthebain oder analoga
EP2402346A1 (en) 2005-11-22 2012-01-04 Controlled Chemicals, Inc. Processes for reducing contaminating Michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (ja) 2006-03-02 2015-04-01 マリンクロッド エルエルシー 低レベルのアルファ，ベータ−不飽和ケトン化合物を伴うモルフィナン−６−オン生成物の製造方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CN101652370A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 制备14-羟基可待因酮水平减少的羟考酮的方法
ES2378710T3 (es) 2006-12-04 2012-04-17 Noramco, Inc. Procedimiento para reducir impurezas en la base de oxicodona
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2804101C (en) * 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
IL178038A (en) 2015-10-29
SG170735A1 (en) 2011-05-30
CA2557845C (en) 2013-10-01
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
PL2316837T3 (pl) 2018-07-31
US20190161492A1 (en) 2019-05-30
CN102887903B (zh) 2016-01-27
US20160185789A1 (en) 2016-06-30
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US20150265597A1 (en) 2015-09-24
US20050222188A1 (en) 2005-10-06
US12060361B2 (en) 2024-08-13
PT2305683E (pt) 2015-05-18
MX2020008878A (es) 2020-11-09
US7674798B2 (en) 2010-03-09
TW201509943A (zh) 2015-03-16
DK200700214U1 (da) 2007-11-23
IL235298A (en) 2016-11-30
US20230159548A1 (en) 2023-05-25
US11384091B2 (en) 2022-07-12
TWI483944B (zh) 2015-05-11
US7674799B2 (en) 2010-03-09
MX363228B (es) 2019-03-15
JP4912294B2 (ja) 2012-04-11
SG170736A1 (en) 2011-05-30
HUE028233T2 (en) 2016-12-28
JP2012072162A (ja) 2012-04-12
US20090227615A1 (en) 2009-09-10
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
EP2316837B1 (en) 2018-01-10
PL2319846T3 (pl) 2016-12-30
CY1116327T1 (el) 2017-02-08
EP2426132B1 (en) 2016-01-13
RS57000B1 (sr) 2018-05-31
NZ601326A (en) 2013-10-25
ME02411B (me) 2016-09-20
JP2017125052A (ja) 2017-07-20
ME02482B (me) 2017-02-20
JP5118223B2 (ja) 2013-01-16
US20160175298A1 (en) 2016-06-23
US9777011B2 (en) 2017-10-03
US20160176888A1 (en) 2016-06-23
EP2311839A1 (en) 2011-04-20
JP2015187134A (ja) 2015-10-29
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
HUE036451T2 (hu) 2018-07-30
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
DK2305683T3 (en) 2015-04-07
DK1730151T4 (da) 2020-10-19
JP5543991B2 (ja) 2014-07-09
KR20200000499A (ko) 2020-01-02
PT2316837T (pt) 2018-04-02
US7674800B2 (en) 2010-03-09
CN101812065B (zh) 2012-03-28
SI1730151T1 (sl) 2011-06-30
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
EP1730151A1 (en) 2006-12-13
US20200062772A1 (en) 2020-02-27
EP2426132A1 (en) 2012-03-07
KR20070022033A (ko) 2007-02-23
IL241117B (en) 2020-06-30
DK200700214U3 (da) 2008-02-08
US20200087316A1 (en) 2020-03-19
AP2006003738A0 (en) 2006-10-31
EP2314589A1 (en) 2011-04-27
US20180022754A1 (en) 2018-01-25
CR8593A (es) 2007-07-19
KR20120106784A (ko) 2012-09-26
SI2316837T1 (en) 2018-05-31
NO20064935L (no) 2006-12-18
ATE501150T1 (de) 2011-03-15
CA2774121A1 (en) 2005-10-20
FIU20070284U0 (fi) 2007-07-04
HRP20110425T1 (en) 2011-07-31
KR20110110377A (ko) 2011-10-06
SI2319846T1 (sl) 2016-08-31
US20160175299A1 (en) 2016-06-23
RS51693B (sr) 2011-10-31
AU2005230826C1 (en) 2014-10-16
EP2305683B1 (en) 2015-01-28
US20150265598A1 (en) 2015-09-24
US20160251363A1 (en) 2016-09-01
DK2426132T3 (en) 2016-04-04
US20130005977A1 (en) 2013-01-03
DE202005021371U1 (de) 2007-10-25
TW201231469A (en) 2012-08-01
SI2305683T1 (sl) 2015-04-30
ES2665287T3 (es) 2018-04-25
US10696684B2 (en) 2020-06-30
HRP20160885T1 (hr) 2016-09-23
US20070179169A1 (en) 2007-08-02
KR20140021716A (ko) 2014-02-20
HRP20180407T1 (hr) 2018-04-20
US20160185790A1 (en) 2016-06-30
AU2009200335A1 (en) 2009-02-26
US20160250204A1 (en) 2016-09-01
CA2557845A1 (en) 2005-10-20
ES2938727T3 (es) 2023-04-14
NO337669B1 (no) 2016-05-30
HRP20110425T4 (hr) 2020-11-27
DK2316837T3 (en) 2018-04-16
EP1730151A4 (en) 2007-05-23
HRP20160223T1 (hr) 2016-03-25
KR20180088505A (ko) 2018-08-03
MY143205A (en) 2011-03-31
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
MA28492B1 (fr) 2007-03-01
AU2005230826A1 (en) 2005-10-20
RS51693B2 (sr) 2021-02-26
MY154985A (en) 2015-08-28
US20070117831A1 (en) 2007-05-24
CY1117841T1 (el) 2017-05-17
KR20140133615A (ko) 2014-11-19
ES2535618T3 (es) 2015-05-13
EP2319846B1 (en) 2016-05-04
RS54941B1 (sr) 2016-11-30
DE602005026786D1 (de) 2011-04-21
PL2426132T3 (pl) 2016-06-30
PL1730151T5 (pl) 2023-09-18
US20160251365A1 (en) 2016-09-01
IL214050A (en) 2013-09-30
IL213889A (en) 2012-06-28
EP1730151B2 (en) 2020-09-16
BRPI0508758A (pt) 2007-08-28
IL213889A0 (en) 2011-07-31
US8822687B2 (en) 2014-09-02
EA013208B1 (ru) 2010-04-30
US20100152449A1 (en) 2010-06-17
US10407434B2 (en) 2019-09-10
KR20090104145A (ko) 2009-10-05
CN102838607A (zh) 2012-12-26
LT2314589T (lt) 2023-06-12
AR049012A1 (es) 2006-06-21
AT9952U1 (de) 2008-06-15
EP1730151B1 (en) 2011-03-09
JP2007531756A (ja) 2007-11-08
KR101410141B1 (ko) 2014-06-25
US20160185788A1 (en) 2016-06-30
PT2426132E (pt) 2016-03-31
SI1730151T2 (sl) 2021-03-31
IL213888A0 (en) 2011-07-31
RS53891B1 (sr) 2015-08-31
CN102838607B (zh) 2016-08-03
CY1117228T1 (el) 2017-04-05
US7129248B2 (en) 2006-10-31
PL1730151T3 (pl) 2011-08-31
TWI365880B (en) 2012-06-11
CY1120171T1 (el) 2018-12-12
US20230365578A1 (en) 2023-11-16
CN102127086A (zh) 2011-07-20
JP2011157370A (ja) 2011-08-18
CA2913355C (en) 2021-04-20
US10689389B2 (en) 2020-06-23
CR20110376A (es) 2011-09-19
US9073933B2 (en) 2015-07-07
HK1155728A1 (en) 2012-05-25
HUE029913T2 (en) 2017-04-28
KR101200700B1 (ko) 2012-11-13
CN101812065A (zh) 2010-08-25
CA2774121C (en) 2016-02-16
AU2009200335B2 (en) 2011-07-28
CN102887903A (zh) 2013-01-23
MY172063A (en) 2019-11-13
HK1155729A1 (en) 2012-05-25
SG10201406658VA (en) 2014-12-30
KR20120046309A (ko) 2012-05-09
CY1111487T1 (el) 2015-08-05
FI7843U1 (fi) 2008-04-28
WO2005097801A1 (en) 2005-10-20
ME01299B (me) 2011-10-31
IL213890A (en) 2015-10-29
JP2014139205A (ja) 2014-07-31
RS54598B1 (sr) 2016-08-31
ES2585576T3 (es) 2016-10-06
EP2305683B2 (en) 2024-09-11
EP2314589B1 (en) 2022-12-28
EP2316837A1 (en) 2011-05-04
IL178038A0 (en) 2006-12-31
US10259819B2 (en) 2019-04-16
IL213890A0 (en) 2011-07-31
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
DK2319846T3 (en) 2016-08-15
AU2005230826B2 (en) 2008-11-06
US20210094963A1 (en) 2021-04-01
US20150258086A1 (en) 2015-09-17
EA200601520A1 (ru) 2007-02-27
EP2305683A1 (en) 2011-04-06
LT2316837T (lt) 2018-04-10
IL213891A0 (en) 2011-07-31
BRPI0508758B8 (pt) 2021-05-25
ME03068B (me) 2019-01-20
CA2913355A1 (en) 2005-10-20
PE20050880A1 (es) 2005-11-16
ECSP066953A (es) 2006-12-20
SI2426132T1 (sl) 2016-04-29
EP2319846A1 (en) 2011-05-11
CN1960994A (zh) 2007-05-09
IL241117A0 (en) 2015-11-30
IL214050A0 (en) 2011-08-31
HK1098745A1 (en) 2007-07-27
ZA200607181B (en) 2007-11-28
JP5378486B2 (ja) 2013-12-25
US20160251364A1 (en) 2016-09-01
EP2305683B8 (en) 2015-03-04
US20160264588A1 (en) 2016-09-15
JP2018184462A (ja) 2018-11-22
KR20100069719A (ko) 2010-06-24
US20160176889A1 (en) 2016-06-23
ES2362282T5 (es) 2021-06-24
US20060173029A1 (en) 2006-08-03
PT2319846T (pt) 2016-08-12
JP2012188439A (ja) 2012-10-04
DK1730151T3 (da) 2011-06-20
US20210198268A1 (en) 2021-07-01
KR20130020962A (ko) 2013-03-04
US9522919B2 (en) 2016-12-20
JP6503392B2 (ja) 2019-04-17
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
ES2362282T3 (es) 2011-06-30
BRPI0508758B1 (pt) 2018-10-09
CN1960994B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
US12060361B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
AU2017204741B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
AU2011213801B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 30 MAR 2025 BY FB RICE

Effective date: 20140911

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2018 BY FB RICE

Effective date: 20140911

EXPY Patent expired